Role of PSA and its indices in determining the need for repeat prostate biopsies

Urology

Volumn 50, Issue 1, 1997, Pages 66-72

  Ukimura, O ^a   Durrani, O ^a   Joseph Babatan, R ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0030809483     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00116-7     Document Type: Article

References (22)

1. Keetch DW, Catalona WJ, and Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151: 1571-1574, 1994.
2. Lui PD, Terris MK, McNeal JE, and Stamey TA: Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer. J Urol 153: 1000-1003, 1995.
3. Benson MC, Whang IS, Olsson CA, McMahon DJ, and Cooner WH: The use of prostatic specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821, 1992.
4. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
5. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andrew R, Fozard JL, and Walsh PC: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
6. Babaian RJ, Kojima M, Ramirez El, and Johnston DA: Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. J Urol 156: 432-437, 1996.
7. Babaian RJ, Miyashita H, Evans RB, von Eschenbach AC, and Ramirez EI: An early detection program for prostate cancer. Results and identification of a high-risk patient population. Urology 37: 193-197, 1991.
8. Babaian RJ, Miyashita H, Evans RB, and Ramirez EI: The distribution of prostate-specific antigen in men without clinical or pathological evidence of prostate cancer. Relationship to gland volume and age. J Urol 147: 837-840, 1992.
9. Hodge KK, McNeal JE, Terris MK, and Stamey TA: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142: 71-75, 1989.
10. Stamey TA: Making the most out of six systematic sextant biopsies. Urology 45: 2-12, 1995.
11. Hanley JA, and McNeil BJ : The meaning and use of the area under a receiver operating characteristics (ROC) curve. Radiology 143: 29-36, 1982.
12. Hanley JA, and McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843, 1983.
13. Brawer MK, Aramburu EAG, Chen GL, Preston SD, and Ellis WJ: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 150: 369-373, 1993.
14. Bare R, Hart L, and McCullough DL: Correlation of prostate specific antigen and prostate-specific antigen density with outcome of prostate biopsy. Urology 43: 191-196, 1994.
15. Hayward RJ, Brawer MK, Ellis WJ, Chetner MP, and Preston SD: Age adjusted serum prostate specific antigen (PSA) in the diagnosis of prostate cancer in men undergoing ultrasound guided biopsy (abstract). J Urol 151: 403A, 1994.
16. Smith DS, and Catalona WJ: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 152: 1163-1167, 1994.
17. Mettlin C, Littlup PJ, Kane RA, Murphy GP, Lee F, Chelsey A, Badalament R, and Mostofi FK: Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from American Cancer Society National Prostate Cancer Detection Project. Cancer 74: 1615-1620, 1994.
18. Prestigiacomo AF, Lilja H, Pettersson K, Wolfert RL, and Stamey TA: A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 156: 350-354, 1996.
19. Stamey TA, Barnhill SD, Zhang Z, Madyastha KR, Prestigiacomo AF, Jones K, and Chan D: Effectiveness of ProstAsure in detecting prostate cancer (PCa) and benign prostatic hyperplasia (BPH) in men age 50 and older (abstract). J Urol 155: 436A, 1996.
20. Daneshgari F, Taylor GD, Miller GJ, and Crawford ED: Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 45: 604-609, 1995.
21. Epstein JI, Walsh PC, Carmichael M, and Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271: 368-374, 1994.
22. Weldon VE, Tavel FR, Neuwirth H, and Cohen R: Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. J Urol 154: 1074-1077, 1995.